Research Article

Definition of a Novel Cuproptosis-Relevant lncRNA Signature for Uncovering Distinct Survival, Genomic Alterations, and Treatment Implications in Lung Adenocarcinoma

Figure 8

Clinical therapeutic benefit of the cuproptosis-relevant lncRNA signature for chemotherapy and small molecule compounds. (a) Boxplots displaying the estimated clinical chemotherapeutic sensitivity in low- and high-risk subsets. (b) Correlations of risk score with AUC values of CTRP-derived small molecule compounds (left) and comparison of AUC values between low- and high-risk subsets (right). (c) Associations of risk score with AUC values of PRISM-derived small molecule compounds (left) and comparison of AUC values between low- and high-risk subsets (right). ; .
(a)
(b)
(c)